Identity, mechanisms and early life impacts of transporter interfering compounds
转运蛋白干扰化合物的特性、机制和早期生命影响
基本信息
- 批准号:10179393
- 负责人:
- 金额:$ 55.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneABCC1 geneABCG2 geneAddressAffectAffinityAnimal ModelAnimalsAntibodiesBindingBiochemicalBiological AssayBiological ModelsBiophysicsCarrier ProteinsCell Differentiation processCellsCellular AssayChemical ExposureChemicalsClustered Regularly Interspaced Short Palindromic RepeatsComplexCryoelectron MicroscopyDataDevelopmentDiseaseElderlyEmbryoEmbryonic DevelopmentExposure toFamilyFishesFunctional disorderGeneticGerm LinesGoalsGrowthHealthHumanImageIn VitroKnock-outLaboratory Molecular EvolutionLifeLigandsLiquid substanceMaternal-fetal medicineMeasuresModelingMolecularMolecular StructureMolecular TargetMusPerformancePharmaceutical PreparationsPredispositionProgram DevelopmentRegulationReproductive HealthResearchResearch PersonnelResistanceResolutionRiskRoleSea UrchinsSignal TransductionSomatic CellStructureStructure of primordial sex cellSystemTechnologyTeratogensTestingTimeToxicant exposureTranslatingUmbilical Cord BloodUrsidae FamilyUterusX-Ray CrystallographyXenobioticsZebrafishdata modelingearly life exposureenvironmental chemicalexperimental studyexposed human populationhuman embryonic stem cellinhibitor/antagonistinnovationinsightnanobodiespollutantpollutant interactionprenatal exposurereproductivereproductive fitnessreproductive system disordertoxicanttranscriptome
项目摘要
PROJECT SUMMARY
Prenatal exposures to environmental chemicals have been shown to cause adverse later life health effects,
often involving disorders of reproductive dysfunction. The overall goal of this research is to understand the
mechanisms governing accumulation of environmental chemicals in the embryo, so that we can predict and
mitigate the negative effects of these exposures. In this proposal, we address two key questions with regard to
xenobiotic accumulation in the embryo, with a specific focus on the role of xenobiotic transporters during
primordial germ cell (PGC) formation. First, we ask how the program of development leads to changes in
xenobiotic transporter expression, and thus generates windows of susceptibility or resistance to xenobiotic
accumulation. Second, we ask how real-world chemical mixtures, containing both substrates and inhibitors of
transporters, impact the efficacy of this conserved, protective system. Aim 1 uses a powerful in vitro molecular
evolution technology to rapidly evolve, validate, and use antibody-like binders called nanobodies to
characterize xenobiotic transporter proteins in human PGC-like cells (PGLCs) and in model organism embryos
(sea urchin and zebrafish). Aim 2 applies biochemical and cellular approaches to determine relevant
environmental ligands of human and model system xenobiotic transporters, and takes advantage of a powerful
molecular structure determination pipeline to dissect the molecular mechanisms of these interactions. Aim 3
uses models and molecular targets from Aims 1 and 2 to test the hypothesis that PGCs are vulnerable to the
interfering effects of environmental chemicals on the transporter defense system, and that disruption of this
system leads to decreased reproductive fitness after xenobiotic challenge. This results will provide new
insights into how environmental and developmental factors act in combination to govern the susceptibility of
the nascent embryonic germ line to teratogens.
项目概要
产前接触环境化学物质已被证明会对以后的健康产生不利影响,
常涉及生殖功能障碍疾病。这项研究的总体目标是了解
控制胚胎中环境化学物质积累的机制,以便我们可以预测和
减轻这些风险的负面影响。在本提案中,我们解决了两个关键问题:
胚胎中的异生素积累,特别关注异生素转运蛋白在胚胎发育过程中的作用
原始生殖细胞(PGC)的形成。首先,我们要问发展计划如何导致变化
异生物质转运蛋白表达,从而产生对异生物质的敏感性或抗性窗口
积累。其次,我们询问现实世界中含有底物和抑制剂的化学混合物如何
转运蛋白,影响这个保守的保护系统的功效。 Aim 1 使用强大的体外分子
快速进化、验证和使用称为纳米抗体的抗体样结合物的进化技术
表征人类 PGC 样细胞 (PGLC) 和模型生物胚胎中的异生物质转运蛋白
(海胆和斑马鱼)。目标 2 应用生化和细胞方法来确定相关的
人类和模型系统外源转运蛋白的环境配体,并利用强大的优势
分子结构测定管道来剖析这些相互作用的分子机制。目标 3
使用目标 1 和 2 中的模型和分子靶标来检验 PGC 易受
环境化学物质对转运蛋白防御系统的干扰作用,以及对该系统的破坏
系统导致外源物质挑战后生殖适应性下降。这一结果将提供新的
深入了解环境和发育因素如何共同作用来控制易感性
新生胚胎生殖系致畸。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEOFFREY A CHANG其他文献
GEOFFREY A CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEOFFREY A CHANG', 18)}}的其他基金
Biosynthesis of marine terpenoid natural products
海洋萜类天然产物的生物合成
- 批准号:
10737210 - 财政年份:2023
- 资助金额:
$ 55.86万 - 项目类别:
Synthetically-evolved and engineered Nanobodies selective for Cb isoforms of PKA
对 PKA Cb 亚型具有选择性的合成进化和工程纳米抗体
- 批准号:
10525796 - 财政年份:2022
- 资助金额:
$ 55.86万 - 项目类别:
Nanobody inhibitors of proton-sensing G protein-coupled receptors
质子感应 G 蛋白偶联受体的纳米抗体抑制剂
- 批准号:
10216432 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10184466 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别:
Development of low-cost, field-ready nanobodies against snake venom
开发低成本、可现场使用的抗蛇毒纳米抗体
- 批准号:
10255596 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10594973 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
TDP-43 乙酰化、相分离、聚集和抗体介导的降解清除
- 批准号:
10380036 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
- 批准号:
9893680 - 财政年份:2019
- 资助金额:
$ 55.86万 - 项目类别:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
唐氏综合症、早期白内障、眼部疾病和 β-淀粉样蛋白构象异构体
- 批准号:
10018872 - 财政年份:2019
- 资助金额:
$ 55.86万 - 项目类别:
Identity, mechanisms and early life impacts of transporter interfering compounds
转运蛋白干扰化合物的特性、机制和早期生命影响
- 批准号:
10424481 - 财政年份:2018
- 资助金额:
$ 55.86万 - 项目类别:
相似国自然基金
ABCC1基因突变致迟发性聋的耳蜗血管纹氧化应激损伤机制及干预研究
- 批准号:
- 批准年份:2021
- 资助金额:57 万元
- 项目类别:面上项目
遗传性耳聋新的致病基因ABCC1的鉴定及致病机制研究
- 批准号:81873705
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
寡糖基转移酶亚基TUSC3在结直肠癌化疗耐药中的作用及分子机制研究
- 批准号:81672441
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
MRP1/ABCC1基因3'UTR单核苷酸多态性介导miRNA对原发性肝癌多药耐药性的影响
- 批准号:81372579
- 批准年份:2013
- 资助金额:50.0 万元
- 项目类别:面上项目
相似海外基金
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
靶向 eIF4A 并结合免疫疗法克服化疗耐药性
- 批准号:
10544331 - 财政年份:2022
- 资助金额:
$ 55.86万 - 项目类别:
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
靶向 eIF4A 并结合免疫疗法克服化疗耐药性
- 批准号:
10357016 - 财政年份:2022
- 资助金额:
$ 55.86万 - 项目类别:
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
靶向耐药乳腺癌干细胞中的 eIF4A1
- 批准号:
10680365 - 财政年份:2022
- 资助金额:
$ 55.86万 - 项目类别:
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
靶向耐药乳腺癌干细胞中的 eIF4A1
- 批准号:
10366263 - 财政年份:2022
- 资助金额:
$ 55.86万 - 项目类别:
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma
针对转移性骨肉瘤中 ERK-AKT 介导的单细胞药物反应异质性
- 批准号:
10896845 - 财政年份:2021
- 资助金额:
$ 55.86万 - 项目类别: